Insulin Dose Articles & Analysis
5 news found
(the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced that Jeb Besser, the Company's Chief Executive Officer, is scheduled to present at the LD Micro Invitational XII Investor Conference on Wednesday, ...
The consequence of this was at home patients misreading their blood glucose levels as 22mmol/L as opposed to 2.2mmol/L and therefore administering a much larger dose of insulin than was required, leading to diabetic coma. This shows how a small usability oversight can have catastrophic consequences. ...
The company is developing products to optimize insulin dosing and provide automated insulin delivery for people with insulin-requiring diabetes. ...
The trial, called REVITA-T2Di, will evaluate the ability of a single Revita DMR treatment to allow patients currently on insulin therapy but with inadequate glycemic control to achieve durable insulin-free glycemic control. ...
In the INSPIRE study, 16 insulin-treated patients with type 2 diabetes (T2D) underwent a single treatment with Revita DMR after which they ceased insulin therapy and began treatment with GLP-1RA and lifestyle counseling. ...